Maintenance Planning and Quality, topics that are important and have impact around Asset Management
Mary Gorczynski 1100006B54 email@example.com | | Tags:  ibmontwitter eam tivoli asset-management service-management ibmsoftware maximo software maintenance
1 Comments | 3,283 Visits
This is a blog posting from Eric Luyer, Market Manager for IBM Asset Management, Industrial Manufacturing.
It is now around two (2) weeks after the Life Sciences Maximo User Group (Fall) meeting in Atlanta, GA, a 2-day event where the always interactive discussions and presentations dominated the meeting. This time it happened that several presentations covered the very basics of the maintenance management activities such as master maintenance planning, daily planning & scheduling, and also addressed enterprise asset management maturity and quality, etc.
Everyone knows about the importance of managing all assets, taking care of challenges as far as asset availability, asset utilization, reliability and performance go. Questions like: how can you manage the information of asset criticality and perform impact analyses? and most importantly: do you consider where “your areas of opportunity” are in your organization or in your department? Things like: prioritization of opportunities, criticality analysis, predictive maintenance approaches, asset management best-practices, maintenance strategies and measurable goals are the things to think about and help to define any gaps into your information system.
If we talk about Maintenance Excellence, it appears that only 5% of companies operate in this area and 30% of these companies gain around 30% lower costs than competitors if they are using Maintenance Excellence programs.
It is important to realize and certainly know where a company is currently positioning on the scale of enterprise asset management lifecycle maturity…
Are you in the so-called predictive phase, where you are able to measure, trend and analyse available information and where you can calculate the return of investments of the actions excuted; or are you in the so-called reliability phase where you are able to perform criticality-driven and risk-based analyses, include design changes, key performance indicators for quality and performance management, etc.; or are you really operating in a true enterprise-wide environment with a center of excellence approach and true focus on ROI?
According to one of the presenters at this last Life Sciences Maximo User Group meeting on these topics - Mike Greenholz of GenesisSolutions, an Enterprise Asset Management assessment can help to get a clear understanding of the strengths and weaknesses of the current asset management program currently in use. This assessment can than result in a recommended list of detailed actions that can improve performance, when implemented. Or the foundation of a Maintenance Master plan combined with tools to conduct a periodic gap analysis to support the maintenance master plan and a tool to track and report progress and performance of this plan’s execution.
This is certainly a good example of an interesting topic to talk about in user group meetings, and to listen to how other companies are managing this kind of information and to learn from each other. You can imagine that this kind of information is well received and leads to interesting discussions.
Another interesting topic was around a good understanding of the quality and testing procedures of software – specifically in a life sciences/pharmaceutical environment where regulatory compliance and validation is an important topic. When validation projects are in the plan, it is strongly recommended to involve the quality (QA) department in your organization as soon as possible in the process. To explain the impact of the changes and how it effects positively the quality management of the processes involved. Also explain your plan and what the impact and benefits are for the end user community in the organization. If Quality Management understands the processes and impact, it will make the validation and acceptance easier.
It is important to realize that the IBM Maximo Asset Management software solution is providing all of the information to meet requirements to manage electronic signatures and audits as outlined in the FDA regulation 21 CFR part 11. Also, based on the current capabilities of the Maximo software solution, it meets the requirements as outlined in the GAMP5 standard as defined by ISPE (International Society of Pharmaceutical Engineers). However it will be always the responsibility of an organization to fulfil the compliance regulations of FDA in situations that software or information systems needs to be validated.
It is important to mention that we in IBM are currently working very closely with some key customers in Life Sciences/Pharma to come up with more detailed information in the case of new software versions or releases and how to best make software upgrade and validation projects smoother and more efficient for the organization. In the coming months and certainly at the next user group meeting, this important topic needs to have a follow-up with results that will be presented to the group.
I hope that you again have enjoyed the information I shared with you. Thanks for reading and if have comments, please let me know.
Look forward to my next blog probably early next year already. With a fresh mind I will touch again on an interesting topic.
Eric Luyer, Market Manager Asset Management (Industrial/Manufacturing), IBM - Tivoli